Thalia Therapeutics plc to acquire Sanmirna Therapeutics Inc

Thalia Therapeutics plc has agreed to acquire Sanmirna Therapeutics Inc in a strategic acquisition within the healthcare sector. The transaction, which was announced and completed on 17 July 2026, involves a consideration structure comprising shares and loan notes. The buyer is based in the United Kingdom, while the specific country of the target is not reported. The financial value of the deal has not been disclosed, and no currency was reported in the available data. This acquisition represents a significant move for Thalia Therapeutics to expand its portfolio through the integration of Sanmirna’s assets and capabilities. The deal structure suggests a focus on long-term alignment between the entities through equity and debt instruments.

The transaction has been successfully completed as of the announcement date. Regulatory approvals and other customary closing conditions were satisfied to finalise the acquisition. This deal marks the formal integration of Sanmirna Therapeutics Inc into the Thalia Therapeutics group. The completion signifies the end of the negotiation phase and the beginning of operational consolidation. Stakeholders can expect the combined entity to pursue its strategic objectives in the healthcare market. The lack of disclosed valuation details keeps the financial specifics private, but the structural elements indicate a complex financial arrangement. The management teams are now focused on realising the synergies expected from this union.